


Ataxia: age and vaccine distribution, VAERS data* (U.S. and foreign), 1990.07–2024.08.30[†]

Draft v32.5



n Novavax reports = 1
n Astrazeneca reports = 0

	Janssen COVID-19	Moderna COVID-19	Pfizer/BioNTech COVID-19	Unknown manufacturer COVID-19	All COVID-19 2020.12.14–2024.08.30	All non-COVID-19 1990.07–2020.12.13
<i>n</i> VAERS IDs	40	171	618	5	835	811
μ , Mean ^{**}	52.8	57.3	56.7	57.2	56.6	22.4
\hat{x} , Median ^{**}	52.5	61.0	60.0	57.0	60.0	12.0
σ , Standard deviation ^{**}	17.5	18.2	19.9	10.8	19.4	25.2
γ , Skewness ^{**}	-0.2	-0.6	-0.6	0.6	-0.6	-0.6
<i>n</i> Hospitalized	29	78	402	3	512	523
<i>n</i> Life threatening	3	14	70	0	87	67
<i>n</i> Recovered	7	42	65	1	115	221
<i>n</i> Not recovered	27	92	476	3	599	320
<i>n</i> Died	0	4	10	0	14	12

[†]Terms queried in SYMPTOM fields 1–5 include: ataxia (all types), dystaxia, and hemiataxia.

[‡]Onset of symptoms post vaccine. *n* IDs are all COVID-19.

^{**}NLP was used to extract age values from SYMPTOM TEXT and fill in missing data. Remaining reports with unknown age are neither plotted, nor included in calculations, but are included in subtotals. [Ⓔ]Symbols link to OpenVAERS.

*VAERS disclaimer (excerpts): "... VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also known as 'safety signals'." "The inclusion of events in VAERS data does not infer causality." vaers.hhs.gov